PE20010700A1 - Compuestos de bencilaminopiperidina sustituidos - Google Patents
Compuestos de bencilaminopiperidina sustituidosInfo
- Publication number
- PE20010700A1 PE20010700A1 PE2001000276A PE0002762001A PE20010700A1 PE 20010700 A1 PE20010700 A1 PE 20010700A1 PE 2001000276 A PE2001000276 A PE 2001000276A PE 0002762001 A PE0002762001 A PE 0002762001A PE 20010700 A1 PE20010700 A1 PE 20010700A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- phenylpiperidine
- benzyl
- sunburns
- trifluoromethyl
- Prior art date
Links
- QACOELYINOMVBY-UHFFFAOYSA-N n-benzylpiperidin-1-amine Chemical class C=1C=CC=CC=1CNN1CCCCC1 QACOELYINOMVBY-UHFFFAOYSA-N 0.000 title 1
- 206010042496 Sunburn Diseases 0.000 abstract 4
- XQDSIGDVDWFZPP-UHFFFAOYSA-N 2-phenylpiperidin-1-amine Chemical compound NN1CCCCC1C1=CC=CC=C1 XQDSIGDVDWFZPP-UHFFFAOYSA-N 0.000 abstract 3
- VXNQJPMCJMJOMN-UHFFFAOYSA-N 1,1-difluoroethane Chemical class C[C](F)F VXNQJPMCJMJOMN-UHFFFAOYSA-N 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 2
- YKNINAKQXAPIKV-ROUUACIJSA-N (2s,3s)-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound FC1=CC=C(C(F)(F)F)C=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 YKNINAKQXAPIKV-ROUUACIJSA-N 0.000 abstract 1
- HYYFWRBWFTVCAE-HKUYNNGSSA-N (2s,3s)-n-[[2-methoxy-5-(1,1,2,2,2-pentafluoroethyl)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(C(F)(F)C(F)(F)F)C=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 HYYFWRBWFTVCAE-HKUYNNGSSA-N 0.000 abstract 1
- LAFDGMMACYWPSJ-UPVQGACJSA-N (2s,3s)-n-[[2-phenoxy-5-(trifluoromethyl)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound N([C@@H]1[C@@H](NCCC1)C=1C=CC=CC=1)CC1=CC(C(F)(F)F)=CC=C1OC1=CC=CC=C1 LAFDGMMACYWPSJ-UPVQGACJSA-N 0.000 abstract 1
- -1 1,2,2,2-TETRAFLUORO-1- (TRIFLUOROMETHYL) ETHYL Chemical class 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- LAPWCYPRCPBMGJ-UHFFFAOYSA-N phenylmethanamine;piperidine Chemical class C1CCNCC1.NCC1=CC=CC=C1 LAPWCYPRCPBMGJ-UHFFFAOYSA-N 0.000 abstract 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A LOS COMPUESTOS BENCILAMINO-PIPERIDINA SUSTITUIDOS DE PREFERENCIA (2S,3S)-3-(2-FLUORO-5-(TRIFLUOROMETIL)BENCIL)AMINO-2-FENILPIPERIDINA, (2S,3S)-3-(2-CLORO-5-(TRIFLUOROMETIL)BENCIL)AMINO-2-FENILPIPERIDINA, (2S,3S)-3-(2-FENOXI-5-(TRIFLUOROMETIL)-BENCIL)AMINO-2-FENILPIPERIDINA, (2S,3S)-2-FENIL-3-(5-(1,2,2,2-TETRAFLUORO-1-(TRIFLUOROMETIL)ETIL)-2-METOXIBENCIL)AMINOPIPERIDINA, (2S,3S)-3-(5-(1,1-DIFLUOROETIL)-2-(TRIFLUOROMETOXI)BENCIL)AMINO-2-FENILPIPERIDINA, (2S,3S)-3-(5-(1,1-DIFLUOROETIL)-2-METOXIBENCIL)AMINO-2-FENILPIPERIDINA; (2S,3S)-3-(2-METOXI-5-(1,1,2,2,2-PENTAFLUOROETIL)BENCIL)AMINO-2-FENILPIPERIDINA; (2S,3S)-3-(2-METOXI-5-(2,2,2-TRIFLUORO-1-HIDROXI-1-(TRIFLUOROMETIL)ETIL)-BENCIL)AMINO-2-FENILPIPERIDINA. LOS COMPUESTOS SON ANTAGONISTAS DE LA SUSTANCIA P Y PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES, TRASTORNOS DEL SNC, ENFERMEDAD INFLAMATORIA, EMESIS, INCONTINENCIA URINARIA, DOLOR, MIGRANA, QUEMADURAS SOLARES, ENFERMEDADES O TRASTORNOS CAUSADOS POR HELICOBACTER PYLORI
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB9500683 | 1995-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010700A1 true PE20010700A1 (es) | 2001-07-09 |
Family
ID=11004362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1996000625A PE1398A1 (es) | 1995-08-24 | 1996-08-21 | Compuestos de bencilaminopiperidina sustituidos |
| PE2001000276A PE20010700A1 (es) | 1995-08-24 | 1996-08-21 | Compuestos de bencilaminopiperidina sustituidos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1996000625A PE1398A1 (es) | 1995-08-24 | 1996-08-21 | Compuestos de bencilaminopiperidina sustituidos |
Country Status (41)
| Country | Link |
|---|---|
| US (1) | US6506775B1 (es) |
| EP (2) | EP0861235B1 (es) |
| JP (1) | JP3084069B2 (es) |
| KR (1) | KR100288673B1 (es) |
| CN (1) | CN1153764C (es) |
| AP (1) | AP643A (es) |
| AR (1) | AR006305A1 (es) |
| AT (2) | ATE258166T1 (es) |
| AU (1) | AU702698B2 (es) |
| BG (1) | BG64126B1 (es) |
| BR (1) | BR9609989A (es) |
| CA (1) | CA2227814C (es) |
| CO (1) | CO4480738A1 (es) |
| CZ (1) | CZ297543B6 (es) |
| DE (2) | DE69631390T2 (es) |
| DK (2) | DK1114817T3 (es) |
| DZ (1) | DZ2086A1 (es) |
| ES (2) | ES2163017T3 (es) |
| HR (1) | HRP960386B1 (es) |
| HU (1) | HU225480B1 (es) |
| IL (1) | IL119078A (es) |
| IS (1) | IS1947B (es) |
| MA (1) | MA23961A1 (es) |
| MX (1) | MX9801467A (es) |
| MY (1) | MY114800A (es) |
| NO (1) | NO310720B1 (es) |
| NZ (1) | NZ308207A (es) |
| OA (1) | OA10666A (es) |
| PE (2) | PE1398A1 (es) |
| PL (1) | PL186773B1 (es) |
| PT (2) | PT1114817E (es) |
| RO (1) | RO119299B1 (es) |
| RU (1) | RU2152930C2 (es) |
| SI (2) | SI1114817T1 (es) |
| SK (1) | SK282925B6 (es) |
| TN (1) | TNSN96107A1 (es) |
| TR (1) | TR199800300T1 (es) |
| TW (1) | TW340842B (es) |
| UA (1) | UA48981C2 (es) |
| WO (1) | WO1997008144A1 (es) |
| YU (1) | YU49122B (es) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9706196A (es) * | 1996-08-14 | 1998-02-28 | Pfizer | Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p. |
| TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
| US6777428B1 (en) | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
| NZ514697A (en) * | 1999-05-06 | 2004-04-30 | Pfizer Prod Inc | Substituted benzolactam compounds |
| RS49964B (sr) | 1999-05-17 | 2008-09-29 | Pfizer Products Inc., | Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli |
| DK1178984T3 (da) | 1999-05-21 | 2003-06-10 | Pfizer Prod Inc | 1-trifluormethyl-4-hydroxy-7-piperidinylaminomethylchroman-derivater |
| PT1095939E (pt) * | 1999-10-18 | 2004-04-30 | Pfizer Prod Inc | Processo para a preparacao de eteres ciclicos de compostos com piperidinilaminometilo |
| CA2324116A1 (en) * | 1999-10-25 | 2001-04-25 | Susan Beth Sobolov-Jaynes | Nk-1 receptor antagonists and eletriptan for the treatment of migraine |
| MXPA02004330A (es) | 1999-11-03 | 2004-07-30 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.. |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| BR0112350A (pt) | 2000-07-11 | 2003-06-24 | Albany Molecular Res Inc | Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico |
| PE20020291A1 (es) * | 2000-08-21 | 2002-04-17 | Hoffmann La Roche | Profarmacos para ligandos del receptor nmda |
| US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
| EP1192952A3 (en) * | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| US6911544B2 (en) | 2002-10-23 | 2005-06-28 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine |
| JP2006523692A (ja) | 2003-04-18 | 2006-10-19 | イーライ リリー アンド カンパニー | ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物 |
| WO2005113503A2 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine |
| CA2573271C (en) | 2004-07-15 | 2015-10-06 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
| KR101589551B1 (ko) | 2005-07-15 | 2016-02-02 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| CA2674436C (en) | 2007-01-10 | 2012-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| CA2682727C (en) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
| EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| EP2247185B1 (en) | 2008-03-03 | 2014-04-16 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| US7951822B2 (en) | 2008-03-31 | 2011-05-31 | Kowa Company, Ltd. | 1,3-dihydroisobenzofuran derivatives |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2429296B1 (en) | 2009-05-12 | 2017-12-27 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| MX2011011901A (es) | 2009-05-12 | 2012-01-20 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas. |
| AU2010247735B2 (en) | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
| JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ｐ５３活性を増大する置換ピペリジン及びその使用 |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| SI2606134T1 (sl) | 2010-08-17 | 2019-08-30 | Sirna Therapeutics, Inc. | RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
| EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US20140045832A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Insulin-Like Growth Factor-1 Receptor Inhibitors |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| CN105050598B (zh) | 2012-09-28 | 2018-04-27 | 默沙东公司 | 作为erk抑制剂的新型化合物 |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| ME02925B (me) | 2012-11-28 | 2018-04-20 | Merck Sharp & Dohme | Kompozicije i postupci za liječenje kancera |
| JP6387013B2 (ja) | 2012-12-20 | 2018-09-12 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｈｄｍ２阻害薬としての置換されたイミダゾピリジン類 |
| EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| KR20210046009A (ko) | 2018-08-07 | 2021-04-27 | 머크 샤프 앤드 돔 코포레이션 | Prmt5 억제제 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
| EP0581777A1 (en) * | 1991-03-26 | 1994-02-09 | Pfizer Inc. | Stereoselective preparation of substituted piperidines |
| EP0589924B1 (en) * | 1991-06-20 | 1996-09-04 | Pfizer Inc. | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles |
| US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| EP0653208A3 (en) * | 1993-11-17 | 1995-10-11 | Pfizer | Substance P antagonists for the treatment or prevention of sunburn. |
| EP0655246A1 (en) * | 1993-11-30 | 1995-05-31 | Pfizer Inc. | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria |
| JP3992733B2 (ja) | 1995-03-27 | 2007-10-17 | 久光製薬株式会社 | ピペリジン誘導体 |
| DK0780375T3 (da) * | 1995-12-21 | 2002-10-07 | Pfizer | 3-((5-substitueret benzyl)amino)-2-phenylpiperidiner som substans P-antagonister |
| US5990125A (en) | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
-
1996
- 1996-06-04 TW TW085106675A patent/TW340842B/zh active
- 1996-06-10 DK DK01108350T patent/DK1114817T3/da active
- 1996-06-10 AU AU57769/96A patent/AU702698B2/en not_active Ceased
- 1996-06-10 ES ES96914375T patent/ES2163017T3/es not_active Expired - Lifetime
- 1996-06-10 PL PL96325332A patent/PL186773B1/pl not_active IP Right Cessation
- 1996-06-10 ES ES01108350T patent/ES2211684T3/es not_active Expired - Lifetime
- 1996-06-10 BR BR9609989A patent/BR9609989A/pt not_active Application Discontinuation
- 1996-06-10 RO RO98-00334A patent/RO119299B1/ro unknown
- 1996-06-10 CN CNB961965037A patent/CN1153764C/zh not_active Expired - Fee Related
- 1996-06-10 DE DE69631390T patent/DE69631390T2/de not_active Expired - Fee Related
- 1996-06-10 AT AT01108350T patent/ATE258166T1/de not_active IP Right Cessation
- 1996-06-10 MX MX9801467A patent/MX9801467A/es active IP Right Grant
- 1996-06-10 NZ NZ308207A patent/NZ308207A/en unknown
- 1996-06-10 SI SI9630670T patent/SI1114817T1/xx unknown
- 1996-06-10 HU HU9901159A patent/HU225480B1/hu not_active IP Right Cessation
- 1996-06-10 DE DE69616817T patent/DE69616817T2/de not_active Expired - Fee Related
- 1996-06-10 SK SK207-98A patent/SK282925B6/sk not_active IP Right Cessation
- 1996-06-10 TR TR1998/00300T patent/TR199800300T1/xx unknown
- 1996-06-10 WO PCT/IB1996/000572 patent/WO1997008144A1/en not_active Ceased
- 1996-06-10 TN TNTNSN96107A patent/TNSN96107A1/fr unknown
- 1996-06-10 PT PT01108350T patent/PT1114817E/pt unknown
- 1996-06-10 SI SI9630374T patent/SI0861235T1/xx unknown
- 1996-06-10 CA CA002227814A patent/CA2227814C/en not_active Expired - Fee Related
- 1996-06-10 UA UA98020924A patent/UA48981C2/uk unknown
- 1996-06-10 EP EP96914375A patent/EP0861235B1/en not_active Expired - Lifetime
- 1996-06-10 CZ CZ0052198A patent/CZ297543B6/cs not_active IP Right Cessation
- 1996-06-10 RU RU98102959/04A patent/RU2152930C2/ru not_active IP Right Cessation
- 1996-06-10 DK DK96914375T patent/DK0861235T3/da active
- 1996-06-10 AT AT96914375T patent/ATE208377T1/de not_active IP Right Cessation
- 1996-06-10 EP EP01108350A patent/EP1114817B1/en not_active Expired - Lifetime
- 1996-06-10 JP JP09510015A patent/JP3084069B2/ja not_active Expired - Fee Related
- 1996-06-10 KR KR1019980701310A patent/KR100288673B1/ko not_active Expired - Fee Related
- 1996-06-10 PT PT96914375T patent/PT861235E/pt unknown
- 1996-08-15 IL IL11907896A patent/IL119078A/xx not_active IP Right Cessation
- 1996-08-20 AR ARP960104045A patent/AR006305A1/es active IP Right Grant
- 1996-08-21 DZ DZ960130A patent/DZ2086A1/fr active
- 1996-08-21 PE PE1996000625A patent/PE1398A1/es not_active Application Discontinuation
- 1996-08-21 PE PE2001000276A patent/PE20010700A1/es not_active Application Discontinuation
- 1996-08-22 HR HR960386A patent/HRP960386B1/xx not_active IP Right Cessation
- 1996-08-23 MY MYPI96003496A patent/MY114800A/en unknown
- 1996-08-23 YU YU47896A patent/YU49122B/sh unknown
- 1996-08-23 MA MA24339A patent/MA23961A1/fr unknown
- 1996-08-24 AP APAP/P/1996/000850A patent/AP643A/en active
- 1996-08-26 CO CO96045248A patent/CO4480738A1/es unknown
-
1997
- 1997-12-30 IS IS4644A patent/IS1947B/is unknown
-
1998
- 1998-02-23 NO NO19980751A patent/NO310720B1/no unknown
- 1998-02-23 OA OA9800023A patent/OA10666A/en unknown
- 1998-02-27 BG BG102288A patent/BG64126B1/bg unknown
-
2000
- 2000-05-01 US US09/564,398 patent/US6506775B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010700A1 (es) | Compuestos de bencilaminopiperidina sustituidos | |
| NZ189418A (en) | Propanolamine and morpholine derivatives pharmaceutical compositions | |
| SE8300736D0 (sv) | Novel pharmacologically active compounds | |
| SE8804629D0 (sv) | New therapeutically active compounds | |
| DK0392959T3 (da) | Anvendelse af Sertindole til behandling af skizofreni | |
| TR199900204T2 (xx) | Fluor i�eren 1,4-diikameli piperidin t�revleri. | |
| BG101110A (bg) | Заместени пиримидинови съединения и тяхното използване | |
| PH25571A (en) | Alpha'-alkyl-4-amino-3-quinolinemethanols, 1-(4-aralkylamino-3-quinolinyl) alaknones, their use as medicaments | |
| FR2711140B1 (fr) | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. | |
| PT770384E (pt) | Composicoes farmaceuticas solidas anidras para utilizacao vaginal | |
| ATE309782T1 (de) | Zusammensetzung zur narbenbehandlung enthaltend eine silikonmischung | |
| SE8804628D0 (sv) | New compounds | |
| AR016384A1 (es) | Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta. | |
| BR9503572A (pt) | Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença | |
| ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
| GR3024058T3 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
| IL79910A (en) | 5,7-dihydro-6-(thi)oxopyrrolo(2,3-f)benzimidazole,-benzothiazole and-benzoxazoles,6-imines thereof,their preparation and pharmaceutical compositions containing them | |
| ES2123568T3 (es) | Derivados de 1-(n-(halo-3-piridilmetil))-n-metilamino-1-alquilamino-2-nitroetileno para la lucha contra pulgas en animales domesticos. | |
| ATE173400T1 (de) | Indolderivate und ihre verwendung | |
| ES511730A0 (es) | "un procedimiento para la preparacion de oxaprocin calcico". | |
| DE2966809D1 (en) | 3,4-diaza-bicyclo(4.1.0)hepten-2-ones-5, process for their preparation and therapeutical compositions containing them | |
| DE60309736D1 (de) | Halogeniertes hydantoin und paraffinwachs enthaltende biozide zusammensetzung | |
| ATE44461T1 (de) | Analgetische zusammensetzungen. | |
| ITRM910963A1 (it) | Composizione farmaceutica effervescente anticefalalgica e suo impiego | |
| IT1296613B1 (it) | Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |